20 companies in the United States to make a joint statement in Tianjin

Not long ago, some mass media on the adverse reaction of Nimesulide continued to hype, seriously misleading the public, doctors and the vast majority of patients, but also to the production enterprises caused significant economic losses and goodwill crisis.　　March 4, Tianjin Pharmaceutical Research Institute Pharmaceutical Limited Liability company, Hainan Canchi Pharmaceutical Co., Ltd. 20 Seretide Enterprises in Tianjin convened Nimesulide Industry development seminar, and signed a joint statement. The statement said that Nimesulide has been widely used in many countries around the world and has been listed in China for more than more than 10 years. In our country, nimesulide is a prescription drug, approved by the state to be used for child fever. A large number of literatures at home and abroad show that nimesulide has similar adverse reactions to similar drugs. The specification of the indications, the use of the crowd, attention, etc. have made clear restrictions.　　The statement advocates the legitimate competition of pharmaceutical enterprises, abide by business ethics, fulfill social responsibility, build up industrial harmony, and provide quality products and services for the masses of patients. The Meeting also invited industry experts to talk about the establishment of drug alert and prevention information system issues, exchange of nimesulide products since the listing of sales and clinical information feedback, adverse reaction monitoring work.